Tumor Suppressor Gene Therapy for Brain Tumors

[1]  R. Alemany,et al.  Suppression of human glioma growth by adenovirus-mediated Rb gene transfer , 1998, Neurology.

[2]  W. Yung,et al.  Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro , 1997, Oncogene.

[3]  T. McDonnell,et al.  Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. , 1997, Journal of the National Cancer Institute.

[4]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[5]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[6]  T. Mikkelsen,et al.  Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. , 1996, Cancer research.

[7]  D. Curiel,et al.  Targeted gene delivery by tropism-modified adenoviral vectors , 1996, Nature Biotechnology.

[8]  D. Brough,et al.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types , 1996, Nature Biotechnology.

[9]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[10]  A. Kyritsis,et al.  Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. , 1996, Oncogene.

[11]  C. Harris,et al.  Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. , 1996, Journal of the National Cancer Institute.

[12]  H. Antoniades,et al.  Cell-cycle regulator cyclin D1 mRNA and protein overexpression occurs in primary malignant gliomas. , 1996, International journal of oncology.

[13]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[14]  K. Walsh,et al.  Resistance to Apoptosis Conferred by Cdk Inhibitors During Myocyte Differentiation , 1996, Science.

[15]  A. Kamb,et al.  Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. , 1996, Cancer research.

[16]  R. Lotan,et al.  Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. , 1996, Cancer research.

[17]  M. Berger,et al.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. , 1996, Cancer research.

[18]  W. Benedict,et al.  Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. , 1996, Cancer research.

[19]  J. Gutterman,et al.  Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. , 1996, Oncogene.

[20]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[21]  A. Ross,et al.  The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells , 1996, Molecular and cellular biology.

[22]  P. Seth,et al.  Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. , 1996, Cancer research.

[23]  H. Shepard,et al.  Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. , 1996, Cancer gene therapy.

[24]  W. Yung,et al.  Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. , 1996, Cancer research.

[25]  K. Drazan,et al.  Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. , 1996, The Journal of urology.

[26]  R. Bookstein,et al.  p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. , 1996, Seminars in oncology.

[27]  J. Bruner,et al.  Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. , 1996, Oncogene.

[28]  J. Bruner,et al.  Mutations of the p16 gene in gliomas. , 1996, Oncogene.

[29]  Scanlon Kj,et al.  Cancer gene therapy--clinical perspective 1995. , 1996 .

[30]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.

[31]  F. Graham,et al.  Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. , 1995, Human gene therapy.

[32]  Q. Wang,et al.  A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. , 1995, Gene therapy.

[33]  A. Passaniti,et al.  Adenovirus‐mediated gene transfer of wild‐type p53 results in melanoma cell apoptosis in vitro and in vivo , 1995, International journal of cancer.

[34]  J. Bruner,et al.  Increased levels of p21WAF1/Cip1 in human brain tumors. , 1995, Oncogene.

[35]  Jianxiang,et al.  In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. , 1995, Cancer research.

[36]  J. Vos.  Viruses in Human Gene Therapy , 1995, Springer Netherlands.

[37]  A M Goldstein,et al.  Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. , 1995, The New England journal of medicine.

[38]  A. Passaniti,et al.  Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. , 1995, Cancer research.

[39]  G. Stark,et al.  p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Z. Oltvai,et al.  Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Kay,et al.  Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. , 1995, Human gene therapy.

[42]  C. Cordon-Cardo,et al.  Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line , 1995, Neurology.

[43]  T. McDonnell,et al.  Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. , 1995, Cancer research.

[44]  F. Haluska,et al.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.

[45]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[46]  J. Bartek,et al.  Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.

[47]  B. Badie,et al.  Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. , 1995, Neurological research.

[48]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[49]  C. Caskey,et al.  Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Oren,et al.  p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. , 1995, Oncogene.

[51]  A. Ligon,et al.  Two tumor suppressive loci on chromosome 10 involved in human glioblastomas , 1995, Genes, chromosomes & cancer.

[52]  W. Cavenee,et al.  Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. , 1995, Cancer research.

[53]  C. Bucana,et al.  Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. , 1995, Cancer gene therapy.

[54]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[55]  K. Roemer,et al.  Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[56]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[57]  T. Shenk.  Group C Adenoviruses as Vectors for Gene Therapy , 1995 .

[58]  M. Perricaudet,et al.  Adenovirus-mediated In Vivo Gene Therapy , 1995 .

[59]  W. Cavenee,et al.  Genetics and malignant progression of human brain tumours. , 1995, Cancer surveys.

[60]  A. Loewy,et al.  Viral vectors : gene therapy and neuroscience applications , 1995 .

[61]  A. Kaye,et al.  Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. , 1995, Cancer research.

[62]  D. Lawrence,et al.  Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro , 1994, Journal of the Neurological Sciences.

[63]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[64]  G. Finocchiaro,et al.  Mutation rate of the CDKN2 gene in malignant gliomas. , 1994, Cancer research.

[65]  G. Reifenberger,et al.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.

[66]  K. Kinzler,et al.  Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.

[67]  J. Shay,et al.  Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. , 1994, Cancer research.

[68]  C. James,et al.  CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. , 1994, Cancer research.

[69]  D. Louis,et al.  The retinoblastoma gene is involved in malignant progression of astrocytomas , 1994, Annals of neurology.

[70]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[71]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[72]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[73]  D. Sidransky,et al.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.

[74]  M. Oren.  Relationship of p53 to the control of apoptotic cell death. , 1994, Seminars in cancer biology.

[75]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[76]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[77]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[78]  H. Saya,et al.  Germline p53 gene mutations in subsets of glioma patients. , 1994, Journal of the National Cancer Institute.

[79]  Erwin G. Van Meir,et al.  Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.

[80]  E. Vuorio,et al.  Differential expression of myc, max and RB1 genes in human gliomas and glioma cell lines. , 1994, British Journal of Cancer.

[81]  M. Csete,et al.  In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection. , 1994, Surgery.

[82]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[83]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[84]  P. Kleihues,et al.  p53 protein accumulation and gene mutations in human glioma cell lines , 1993, International journal of cancer.

[85]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[86]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[87]  J. Roth,et al.  Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. , 1993, BioTechniques.

[88]  E Stubblefield,et al.  Analysis of the functional role of chromosome 10 loss in human glioblastomas. , 1993, Cancer research.

[89]  C. Eng,et al.  Mortality From Second Tumors Among Long-Term Survivors of Retinoblastoma , 1993 .

[90]  C. D. James,et al.  Gene and chromosomal alterations associated with the development of human gliomas , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[91]  R. Neve.  Adenovirus vectors enter the brain , 1993, Trends in Neurosciences.

[92]  M. Perricaudet,et al.  An adenovirus vector for gene transfer into neurons and glia in the brain , 1993, Science.

[93]  Iver Petersen,et al.  Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system , 1993, Molecular carcinogenesis.

[94]  M. Perricaudet,et al.  Transfer of a foreign gene into the brain using adenovirus vectors , 1993, Nature Genetics.

[95]  W. Cavenee,et al.  Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. , 1992, Human pathology.

[96]  P. Kelly,et al.  Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo‐astrocytomas , 1992, Genes, Chromosomes and Cancer.

[97]  R. Godbout,et al.  Lack of expression of tumor-suppressor genes in human malignant glioma cell lines. , 1992, Oncogene.

[98]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[99]  A. Sahin,et al.  Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. , 1992, Journal of the National Cancer Institute.

[100]  Adrian Bird,et al.  The essentials of DNA methylation , 1992, Cell.

[101]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[102]  A. Friedman,et al.  Loss of heterozygosity for 10q loci in human gliomas , 1992, Genes, chromosomes & cancer.

[103]  E. Newcomb,et al.  p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. , 1992, Cancer research.

[104]  T. Mikkelsen,et al.  Clonal expansion of p53 mutant cells is associated with brain tumour progression , 1992, Nature.

[105]  R. Cawthon,et al.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. , 1992, Cancer research.

[106]  R. Weinberg,et al.  Tumor suppressor genes. , 1991, Science.

[107]  Y. Qian,et al.  The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle , 1991, Cell.

[108]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[109]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[110]  G E Moore,et al.  Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. , 1991, Cancer research.

[111]  M. Noble,et al.  Retinoblastoma gene deletions in human glioblastomas. , 1991, Oncogene.

[112]  F. Graham,et al.  Manipulation of adenovirus vectors. , 1991, Methods in molecular biology.

[113]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[114]  C. Cordon-Cardo,et al.  Altered expression of the retinoblastoma gene product in human sarcomas. , 1990, The New England journal of medicine.

[115]  W. Lee,et al.  Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[116]  W. Cavenee,et al.  Molecular Genetics in the Pathology and Diagnosis of Retinoblastoma , 1990, Brain pathology.

[117]  E. Appella,et al.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[118]  D. Bigner,et al.  Cytogenetics of human brain tumors. , 1990, Cancer genetics and cytogenetics.

[119]  H. Hirai,et al.  Overexpression confers an oncogenic potential upon the eph gene. , 1990, Oncogene.

[120]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[121]  A. Pardee.  G1 events and regulation of cell proliferation. , 1989, Science.

[122]  T. Pawson,et al.  High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene , 1989, Molecular and cellular biology.

[123]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[124]  P. L. Chen,et al.  Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. , 1988, Science.

[125]  C. James,et al.  Clonal genomic alterations in glioma malignancy stages. , 1988, Cancer research.

[126]  J. Minna,et al.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. , 1988, Science.

[127]  M. Frommer,et al.  CpG islands in vertebrate genomes. , 1987, Journal of molecular biology.

[128]  P. Kornblith,et al.  Molecular Genetics of Nervous System Tumors , 1994 .

[129]  A. Bird.  CpG-rich islands and the function of DNA methylation , 1986, Nature.

[130]  T. Shows,et al.  Transformation associated p53 protein is encoded by a gene on human chromosome 17 , 1985, Somatic cell and molecular genetics.

[131]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[132]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[133]  M. Green,et al.  Do highly oncogenic group A human adenoviruses cause human cancer? Analysis of human tumors for adenovirus 12 transforming DNA sequences. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[134]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[135]  W. Bancroft,et al.  Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. , 1971, The Journal of infectious diseases.

[136]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[137]  G. Klein,et al.  Suppression of Malignancy by Cell Fusion , 1969, Nature.

[138]  R. Chanock,et al.  IMMUNIZATION WITH TYPES 4 AND 7 ADENOVIRUS BY SELECTIVE INFECTION OF THE INTESTINAL TRACT. , 1963, The American review of respiratory disease.